Recommendation	Insufficient data
Comments	A firm recommendation would be premature. Retrospective cohort study suggests clinical failure more likely in obese patients treated with standard dosing (Diseases 2020;8:E27). However, no data on ceftriaxone PK alterations in obesity are available (Pharmacotherapy 2023;43:226).